【摘要】 目的探讨与血管紧张素Ⅱ1型受体(AT1R)拮抗剂伊贝沙坦降压疗效相关的基因多态性位点。方法152例轻、中度高血压病患者服用伊贝沙坦治疗8周,观察降压疗效,同时采用聚合酶链反应-限制性片断长度多态性对患者血管紧张素-醛固酮系统基因多态性位点AT1R T573C、血管紧张素转换酶(ACE)I/D基因型进行分析。结果携带AT1R 573T等位基因的患者服用伊贝沙坦后,收缩压及脉压降幅明显大于CC基因型患者;在男性患者,基因型为ACE DD的患者舒张压降幅明显大于II型患者;同时携带AT1R 573T和ACE D等位基因的男性患者降压疗效最佳。结论携带AT1R 573T和ACE D等位基因的高血压病患者对伊贝沙坦的降压反应最佳。更多还原

【Abstract】 Objective To determine whether polymorphisms of the renin-angiotensin system can predicts blood pressure-lowering response to angiotensin Ⅱ receptor type-1 antagonists treatment,specially,in response to treatment with irbesartan.Methods 152 patients with mild to moderate essential hypertension were enrolled and treated with irbesartan for 8 weeks,gene polymorphisms of angiotensin Ⅱ type-1 receptor（AT₁R） T573C and angiotensin converting enzyme insertion/deletion（ACE I/D） were detected by PCR-RFLP methods.Results After taking irbesartan,individuals with the AT₁R gene T allele showed a greater reduction in systolic blood pressure and pulse pressure than those with homozygous for C allele did.In males,homozygous of ACE DD showed a greater reduction in diastolic blood pressure than homozygous of II did,and AT₁R T573C and ACE I/D gene polymorphisms showed a synergistic effect on the response to irbesartan.Conclusion AT₁R T573C and ACE I/D gene polymorphisms were related to the blood pressure-lowering response to antihypertensive treatment with irbesartan.更多还原